The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.

doi:10.1007/s10147-014-0761-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.

International journal of clinical oncology - 1 Aug 2015

Ko Ryo, Kenmotsu Hirotsugu, Hisamatsu Yasushi, Akamatsu Hiroaki, Omori Shota, Nakashima Kazuhisa, Oyakawa Takuya, Wakuda Kazushige, Shukuya Takehito, Ono Akira, Imai Hisao, Taira Tetsuhiko, Naito Tateaki, Murakami Haruyasu, Mori Keita, Endo Masahiro, Ohde Yasuhisa, Takahashi Kazuhisa, Takahashi Toshiaki

Abstract excerpt

BACKGROUND: It is unclear whether there is a difference in the effect of gefitinib treatment between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and those with stage IV NSCLC harboring mutations in the epidermal growth factor receptor (EGFR). METHODS: We retrospectively reviewed the medical records of consecutive patients with postoperative recurrent NSCLC (postoperative group) or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Neoplasm Recurrence, Local

Share to Quinazolines

Source

Open in PubMed

Identifiers

PMID: 25343946
DOI: 10.1007/s10147-014-0761-8

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.PMID 25343946Read ↗

Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity Read ↗

Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Efficacy of Osimertinib in Patients With Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations.Semantic proximity Read ↗

The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.Semantic proximity Read ↗

Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.Semantic proximity Read ↗

Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.Semantic proximity Read ↗

Is radical local therapy effective in postoperative recurrent EGFR-mutated non-small cell lung cancer?Semantic proximity Read ↗

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative RecurrenceSemantic proximity Read ↗

Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.Semantic proximity Read ↗

Gefitinib Delays NSCLC Recurrence After Surgery.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.